Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $81 to $83.